id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S7505 R22451 |
Meador (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2020 | Fetal loss (Spontaneous miscarriages and fetal death) | 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.76 [0.12;4.62] C excluded (control group) |
2/99 3/113 | 5 | 99 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S7495 R22421 |
Meador (Levetiracetam) (Controls unexposed, disease free), 2020 | Fetal loss (Spontaneous miscarriages and fetal death) | 1st trimester | prospective cohort | unexposed, disease free excluded | Adjustment: No |
5.47 [0.26;115.30] C excluded (control group) |
2/99 0/106 | 2 | 99 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S7501 R22439 |
Meador (Levetiracetam) (Controls unexposed, sick), 2020 | Fetal loss (Spontaneous miscarriages and fetal death) | 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 0.75 [0.03;16.45] C | 2/99 0/15 | 2 | 99 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8038 R24451 |
Koc (Levetiracetam), 2018 | Intrauterine deaths as a whole | during pregnancy (anytime or not specified) | retrospective cohort | unexposed, sick | Adjustment: No | 0.55 [0.09;3.26] C | 2/30 4/35 | 6 | 30 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8064 R24570 |
Trivedi (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2018 | Spontaneous fetal loss (both spontaneous abortion before 20 weeks of gestation and stillbirths occurring after 20 weeks of gestation) | 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.75 [0.18;3.15] C excluded (control group) |
4/63 4/48 | 8 | 63 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8054 R24555 |
Trivedi (Levetiracetam) (Controls unexposed, sick), 2018 | Spontaneous fetal loss (both spontaneous abortion before 20 weeks of gestation and stillbirths occurring after 20 weeks of gestation) | 1st trimester | prospective cohort | unexposed, sick | Adjustment: Yes | 1.99 [0.29;13.69] | 4/63 5/178 | 9 | 63 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S7759 R22965 |
Vajda (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2018 | Intrauterine foetal death | throughout pregnancy | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.41 [0.09;1.85] C excluded (control group) |
2/129 14/382 | 16 | 129 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S7750 R22956 |
Vajda (Levetiracetam) (Controls unexposed, sick), 2018 | Intrauterine foetal death | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 2.64 [0.24;28.75] | 2/129 1/170 | 3 | 129 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S301 R16637 |
Arkilo (Levetiracetam), 2015 | Unsuccessful pregnancies (miscarriages/stillbirths) | during pregnancy (anytime or not specified) | retrospective cohort | exposed to other treatment, sick | Adjustment: No | 2.44 [0.30;20.12] C | 2/11 2/24 | 4 | 11 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S7815 R23211 |
Tomson (Levetiracetam), 2015 | Intrauterine death | at least 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 1.11 [0.73;1.69] C | 28/324 150/1,910 | 178 | 324 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 6 studies | 1.15 [0.78;1.69] | 202 | 656 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Levetiracetam) (Controls unexposed, sick; 2: Levetiracetam; 3: Levetiracetam) (Controls unexposed, sick; 4: Levetiracetam) (Controls unexposed, sick; 5: Levetiracetam; 6: Levetiracetam;
Asymetry test p-value = 0.5587 (by Egger's regression)
slope=0.0453 (0.1969); intercept=0.2601 (0.4082); t=0.6371; p=0.5587
excluded 8064, 7759, 7505, 7495